Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

kelly smith

- PMLiVE

Catalent preps for complex therapy boom with $1.2bn Paragon buy

Reflects growing investment in cell and gene therapies

- PMLiVE

First-in-class hepatitis B/D drug raises cure hope

Those taking the regimen saw virus levels decline

- PMLiVE

Chi-Med goes for third IPO in Hong Kong

New listing follows first product launch

Cuttsy+Cuttsy awarded IPA Platinum

Cuttsy+Cuttsy awarded CPD Platinum by the IPA

Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation.

Cuttsy + Cuttsy

- PMLiVE

Breaking Bad

Six behaviours separate the good brand teams from the bad

- PMLiVE

The first, my last, my everything

The inescapable rise of patient-centricity

- PMLiVE

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare

- PMLiVE

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

CAR-T player Autolus seeks $100m from follow-on financing

Funds will further develop pipeline

- PMLiVE

Novo Nordisk and Gilead join forces in NASH

Will combine semaglutide with Gilead’s cilofexor and firsocostat

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links